伊马替尼治疗胃肠间质瘤疗效评估标准研究

Analysis on the evaluation criteria for therapeutic effect of imatinib in GIST

目的探讨胃肠间质瘤(GIST)靶向治疗评估新标准。方法分析2004年8月至2010年10月复旦大学附属肿瘤医院行伊马替尼治疗GIST获得完全缓解的4例病人的临床资料,比较术后病理与术前影像学的差异。结果 4例病人中,2例为影像学评估,其中1例同时接受CT和PET-CT评估;另外2例同时接受影像学和病理学评估,两者评估结果完全不同。结论在GIST病人伊马替尼疗效评估中,Choi标准有可能取代RECIST标准,成为新的评估标准。

Objective To explore a new evaluation on target therapy in GIST patients. Methods The clinical data of 4 cases of GIST obtained complete remission after using imatinih between August 2004 and October 2010 at Fudan University Shanghai Cancer Center was analyzed. The imaging by CT or PET-CT scan before operation and pathology results after resection of 4 cases were compared. Results In 4 cases of GIST, 2 cases were evaluated only by imaging （ case 1 was evaluated by both CT and PET-CT）, and another 2 cases were evaluated by both imaging and pathology. CT scans of cases performed resection after imatinib therapy was in contradiction of the findings of histopathological examination. Conclusion The Choi response criteria are superior to the REC1ST criteria, and may become the mainstay in the evaluation of imatinib response in GIST cases.